199 related articles for article (PubMed ID: 16184180)
1. Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath).
Myers GD; Krance RA; Weiss H; Kuehnle I; Demmler G; Heslop HE; Bollard CM
Bone Marrow Transplant; 2005 Dec; 36(11):1001-8. PubMed ID: 16184180
[TBL] [Abstract][Full Text] [Related]
2. Infectious complications associated with alemtuzumab use for allogeneic hematopoietic stem cell transplantation: comparison with anti-thymocyte globulin.
Park SH; Choi SM; Lee DG; Choi JH; Yoo JH; Kim SH; Kim HJ; Cho SG; Eom KS; Lee JW; Min WS; Shin WS; Kim CC
Transpl Infect Dis; 2009 Oct; 11(5):413-23. PubMed ID: 19708893
[TBL] [Abstract][Full Text] [Related]
3. The effects of Campath 1H upon graft-versus-host disease, infection, relapse, and immune reconstitution in recipients of pediatric unrelated transplants.
Shah AJ; Kapoor N; Crooks GM; Weinberg KI; Azim HA; Killen R; Kuo L; Rushing T; Kohn DB; Parkman R
Biol Blood Marrow Transplant; 2007 May; 13(5):584-93. PubMed ID: 17448918
[TBL] [Abstract][Full Text] [Related]
4. Comparable outcomes of matched-related and alternative donor stem cell transplantation for pediatric severe aplastic anemia.
Kennedy-Nasser AA; Leung KS; Mahajan A; Weiss HL; Arce JA; Gottschalk S; Carrum G; Khan SP; Heslop HE; Brenner MK; Bollard CM; Krance RA
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1277-84. PubMed ID: 17162209
[TBL] [Abstract][Full Text] [Related]
5. Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma.
Kröger N; Shaw B; Iacobelli S; Zabelina T; Peggs K; Shimoni A; Nagler A; Binder T; Eiermann T; Madrigal A; Schwerdtfeger R; Kiehl M; Sayer HG; Beyer J; Bornhäuser M; Ayuk F; Zander AR; Marks DI;
Br J Haematol; 2005 Jun; 129(5):631-43. PubMed ID: 15916686
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous alemtuzumab vs ATG in adjusted conditioning for allogeneic transplantation: influence of Campath dose on lymphoid recovery, mixed chimerism and survival.
Juliusson G; Theorin N; Karlsson K; Frödin U; Malm C
Bone Marrow Transplant; 2006 Mar; 37(5):503-10. PubMed ID: 16415894
[TBL] [Abstract][Full Text] [Related]
7. Comparison of two doses of antithymocyte globulin in patients undergoing matched unrelated donor allogeneic stem cell transplantation.
Ayuk F; Diyachenko G; Zabelina T; Wolschke C; Fehse B; Bacher U; Erttmann R; Kröger N; Zander AR
Biol Blood Marrow Transplant; 2008 Aug; 14(8):913-9. PubMed ID: 18640575
[TBL] [Abstract][Full Text] [Related]
8. Retrospective study of alemtuzumab vs ATG-based conditioning without irradiation for unrelated and matched sibling donor transplants in acquired severe aplastic anemia: a study from the British Society for Blood and Marrow Transplantation.
Marsh JC; Pearce RM; Koh MB; Lim Z; Pagliuca A; Mufti GJ; Perry J; Snowden JA; Vora AJ; Wynn RT; Russell N; Gibson B; Gilleece M; Milligan D; Veys P; Samarasinghe S; McMullin M; Kirkland K; Cook G;
Bone Marrow Transplant; 2014 Jan; 49(1):42-8. PubMed ID: 23912664
[TBL] [Abstract][Full Text] [Related]
9. A comparison of Campath and Thymoglobulin as part of the conditioning before allogeneic hematopoietic stem cell transplantation.
Norlin AC; Remberger M
Eur J Haematol; 2011 Jan; 86(1):57-66. PubMed ID: 20942840
[TBL] [Abstract][Full Text] [Related]
10. Impact of serotherapy on immune reconstitution and survival outcomes after stem cell transplantations in children: thymoglobulin versus alemtuzumab.
Willemsen L; Jol-van der Zijde CM; Admiraal R; Putter H; Jansen-Hoogendijk AM; Ostaijen-Ten Dam MM; Wijnen JT; van Kesteren C; Waaijer JL; Lankester AC; Bredius RG; van Tol MJ
Biol Blood Marrow Transplant; 2015 Mar; 21(3):473-82. PubMed ID: 25485863
[TBL] [Abstract][Full Text] [Related]
11. Alemtuzumab, fludarabine and melphalan as a conditioning therapy in severe aplastic anemia and hypoplastic myelodysplastic syndrome--single center experience.
Rzepecki P; Sarosiek T; Szczylik C
Jpn J Clin Oncol; 2006 Jan; 36(1):46-9. PubMed ID: 16423840
[TBL] [Abstract][Full Text] [Related]
12. Addition of ATG to the conditioning regimen is a major determinant for outcome after transplantation with partially lymphocyte-depleted grafts from voluntary unrelated donors.
Schattenberg A; van der Meer A; Preijers F; Schaap N; Rinkes M; van der Maazen R; Allebes W; Joosten I; De Witte T
Bone Marrow Transplant; 2004 Jun; 33(11):1115-21. PubMed ID: 15064694
[TBL] [Abstract][Full Text] [Related]
13. Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis.
Russell JA; Turner AR; Larratt L; Chaudhry A; Morris D; Brown C; Quinlan D; Stewart D
Biol Blood Marrow Transplant; 2007 Mar; 13(3):299-306. PubMed ID: 17317583
[TBL] [Abstract][Full Text] [Related]
14. Bone marrow transplantation in thalassemia major patients using "short" anti-thymocyte globulin therapy in Shiraz, Southern Iran.
Zakerinia M; Khojasteh HN; Ramzi M; Haghshenas M
Transplant Proc; 2005 Dec; 37(10):4477-81. PubMed ID: 16387149
[TBL] [Abstract][Full Text] [Related]
15. Comparable outcome of alternative donor and matched sibling donor hematopoietic stem cell transplant for children with acute lymphoblastic leukemia in first or second remission using alemtuzumab in a myeloablative conditioning regimen.
Kennedy-Nasser AA; Bollard CM; Myers GD; Leung KS; Gottschalk S; Zhang Y; Liu H; Heslop HE; Brenner MK; Krance RA
Biol Blood Marrow Transplant; 2008 Nov; 14(11):1245-52. PubMed ID: 18940679
[TBL] [Abstract][Full Text] [Related]
16. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells.
Hale G; Jacobs P; Wood L; Fibbe WE; Barge R; Novitzky N; Toit C; Abrahams L; Thomas V; Bunjes D; Duncker C; Wiesneth M; Selleslag D; Hidajat M; Starobinski M; Bird P; Waldmann H
Bone Marrow Transplant; 2000 Jul; 26(1):69-76. PubMed ID: 10918407
[TBL] [Abstract][Full Text] [Related]
17. Dose-dependent effects of in vivo antithymocyte globulin during conditioning for allogeneic bone marrow transplantation from unrelated donors in patients with chronic phase CML.
Schleuning M; Günther W; Tischer J; Ledderose G; Kolb HJ
Bone Marrow Transplant; 2003 Aug; 32(3):243-50. PubMed ID: 12858194
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic transplantation of G-CSF mobilized peripheral blood stem cells from unrelated donors: a retrospective analysis.
Bornhäuser M; Theuser C; Soucek S; Hölig K; Klingebiel T; Blau W; Fauser A; Runde V; Schwinger W; Rutt C; Ehninger G
Haematologica; 2000 Aug; 85(8):839-47. PubMed ID: 10942931
[TBL] [Abstract][Full Text] [Related]
19. Prospective, comprehensive, and effective viral monitoring in children undergoing allogeneic hematopoietic stem cell transplantation.
Schönberger S; Meisel R; Adams O; Pufal Y; Laws HJ; Enczmann J; Dilloo D
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1428-35. PubMed ID: 20399877
[TBL] [Abstract][Full Text] [Related]
20. A low incidence of nontuberculous mycobacterial infections in pediatric hematopoietic stem cell transplantation recipients.
Unal E; Yen C; Saiman L; George D; Della-Latta P; van de Ven C; Morris E; Bradley MB; Del Toro G; Garvin J; Bhatia M; Schwartz J; Satwani P; Roman E; Cooney E; Wolownik K; Hawks R; Foley S; Cairo MS
Biol Blood Marrow Transplant; 2006 Nov; 12(11):1188-97. PubMed ID: 17085312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
